


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:02:36Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12407681" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12407681</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-id journal-id-type="pmc-domain-id">3848</journal-id><journal-id journal-id-type="pmc-domain">biorxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title-group><journal-title>bioRxiv</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn><publisher><publisher-name>Cold Spring Harbor Laboratory Preprints</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12407681</article-id><article-id pub-id-type="pmcid-ver">PMC12407681.1</article-id><article-id pub-id-type="pmcaid">12407681</article-id><article-id pub-id-type="pmcaiid">12407681</article-id><article-id pub-id-type="pmid">40909561</article-id><article-id pub-id-type="doi">10.1101/2025.08.21.671546</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>
Quiescent OXPHOS-high triple-negative breast cancer cells that persist after chemotherapy depend on BCL-XL for survival
</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Andrzejewski</surname><given-names initials="S">Slawomir</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Winter</surname><given-names initials="M">Marie</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garcia</surname><given-names initials="LE">Leandro Encarnacao</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Akinrinmade</surname><given-names initials="O">Olusiji</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marques</surname><given-names initials="FDM">Francisco D.M.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zacharioudakis</surname><given-names initials="E">Emmanouil</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Skwarska</surname><given-names initials="A">Anna</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aguirre-Ghiso</surname><given-names initials="J">Julio</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Konopleva</surname><given-names initials="M">Marina</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zheng</surname><given-names initials="G">Guangrong</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fineberg</surname><given-names initials="S">Susan</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="D">Daohong</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gavathiotis</surname><given-names initials="E">Evripidis</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="T">Tao</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dhimolea</surname><given-names initials="E">Eugen</given-names></name></contrib></contrib-group><pub-date pub-type="epub"><day>25</day><month>8</month><year>2025</year></pub-date><issue-id pub-id-type="pmc-issue-id">496186</issue-id><elocation-id>2025.08.21.671546</elocation-id><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-05 09:25:55.133"><day>05</day><month>09</month><year>2025</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License</ext-link>, which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="nihpp-2025.08.21.671546v1.pdf"/><self-uri xlink:href="http://biorxiv.org/lookup/doi/10.1101/2025.08.21.671546">http://biorxiv.org/lookup/doi/10.1101/2025.08.21.671546</self-uri><self-uri content-type="pdf">nihpp-2025.08.21.671546.pdf</self-uri><abstract><title>ABSTRACT</title><p>
The persistent residual tumor cells that survive after chemotherapy are a major cause of treatment failure, but their survival mechanisms remain largely elusive. These cancer cells are typically characterized by a quiescent state with suppressed activity of MYC and MTOR. We observed that the MYC-suppressed persistent triple-negative breast cancer (TNBC) cells are metabolically flexible and can upregulate mitochondrial oxidative phosphorylation (OXPHOS) genes and respiratory function (&#8220;OXPHOS-high&#8221; cell state) in response to DNA-damaging anthracyclines such as doxorubicin, but not to taxanes. The elevated biomass and respiratory function of mitochondria in OXPHOS-high persistent cancer cells were associated with mitochondrial elongation and remodeling suggestive of increased mitochondrial fusion. A genome-wide CRISPR editing screen in doxorubicin-persistent OXPHOS-high TNBC cells revealed BCL-XL gene as the top survival dependency in these quiescent tumor cells, but not in their untreated proliferating counterparts. Quiescent OXPHOS-high TNBC cells were highly sensitive to BCL-XL inhibitors, but not to inhibitors of BCL2 and MCL1. Interestingly, inhibition of BCL-XL in doxorubicin-persistent OXPHOS-high TNBC cells rapidly abrogated mitochondrial elongation and respiratory function, followed by caspase 3/7 activation and cell death. The platelet-sparing proteolysis targeted chimera (PROTAC) BCL-XL degrader DT2216 enhanced the efficacy of doxorubicin against TNBC xenografts
<italic toggle="yes">in vivo</italic>
without induction of thrombocytopenia that is often observed with the first-generation BCL-XL inhibitors, supporting the development of this combinatorial treatment strategy for eliminating dormant tumor cells that persist after treatment with anthracycline-based chemotherapy.
</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>